LABCORP HOLDINGS INC. executive Brian J. Caveney received 3,000 derivative securities on September 1, bringing his total derivative securities holdings to 7,170. The transaction matters to investors because it changes the reported derivative securities position of a senior executive who serves as executive vice president, president of BLS, chief medical officer and chief science officer.

Key Highlights

  • Brian J. Caveney held 7,170 derivative securities after the transaction.
  • The award took place on September 1, 2026.
  • Caveney serves as executive vice president, president of BLS, chief medical officer and chief science officer.

LABCORP HOLDINGS INC. (NYSE: LH) awarded executive Brian J. Caveney 3,000 derivative securities. Caveney’s total derivative securities holdings stood at 7,170 after the transaction.

Caveney’s Derivative Securities Position

The transaction occurred on September 1, 2026. Caveney is identified in the filing as an executive vice president, president of BLS, chief medical officer and chief science officer.